Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy

Yun Jin Lee, hoonchul kang, Joo Hee Seo, Joon Soo Lee, HeungDong Kim

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: This study investigated the efficacy and safety of zonisamide (ZNS) adjunctive therapy in children with intractable epilepsy to existing antiepileptic drugs (AEDs). Methods: A clinical retrospective study was performed from 2003 to 2005 at two tertiary epilepsy centers. We reviewed the data from 163 children (107 boys and 56 girls) who experienced more than four seizures per month, whose seizures were intractable to an initial 2 or more AEDs, and could be followed up for at least 6. months after ZNS adjunctive therapy initiation. Efficacy was estimated by seizure reduction rate according to seizure types including infantile spasms, and adverse events were also measured. Results: Seventy-nine patients (48.5%) out of 163 patients experienced a reduction in seizure frequency of more than 50%, and 25 patients (15.3%) became seizure-free. The rate of seizure reduction greater than 50% in children with partial seizures was 40.5% (17/42) and in children with generalized seizures was 51.2% (62/121). Of 36 patients who manifested mainly myoclonic seizures, 20 patients (55.6%) showed a seizure reduction of more than 50% and 9 patients (25.0%) were seizure-free. Mean maintenance dosage of drug was 8.2. mg/kg/day (range 5.0-16.0. mg/kg/day). Adverse events were documented in 15 children (9.2%), including somnolence (8 patients), fatigue, and anorexia, but all were transient and successfully managed. One patient discontinued ZNS therapy due to acute pancreatitis. Conclusion: ZNS adjunctive therapy is an effective and safe treatment in various childhood intractable epilepsy.

Original languageEnglish
Pages (from-to)208-212
Number of pages5
JournalBrain and Development
Volume32
Issue number3
DOIs
Publication statusPublished - 2010 Mar 1

Fingerprint

zonisamide
Seizures
Therapeutics
Anticonvulsants
Drug Resistant Epilepsy

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

@article{d78934f76f564882b99afe85ae7e021a,
title = "Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy",
abstract = "Purpose: This study investigated the efficacy and safety of zonisamide (ZNS) adjunctive therapy in children with intractable epilepsy to existing antiepileptic drugs (AEDs). Methods: A clinical retrospective study was performed from 2003 to 2005 at two tertiary epilepsy centers. We reviewed the data from 163 children (107 boys and 56 girls) who experienced more than four seizures per month, whose seizures were intractable to an initial 2 or more AEDs, and could be followed up for at least 6. months after ZNS adjunctive therapy initiation. Efficacy was estimated by seizure reduction rate according to seizure types including infantile spasms, and adverse events were also measured. Results: Seventy-nine patients (48.5{\%}) out of 163 patients experienced a reduction in seizure frequency of more than 50{\%}, and 25 patients (15.3{\%}) became seizure-free. The rate of seizure reduction greater than 50{\%} in children with partial seizures was 40.5{\%} (17/42) and in children with generalized seizures was 51.2{\%} (62/121). Of 36 patients who manifested mainly myoclonic seizures, 20 patients (55.6{\%}) showed a seizure reduction of more than 50{\%} and 9 patients (25.0{\%}) were seizure-free. Mean maintenance dosage of drug was 8.2. mg/kg/day (range 5.0-16.0. mg/kg/day). Adverse events were documented in 15 children (9.2{\%}), including somnolence (8 patients), fatigue, and anorexia, but all were transient and successfully managed. One patient discontinued ZNS therapy due to acute pancreatitis. Conclusion: ZNS adjunctive therapy is an effective and safe treatment in various childhood intractable epilepsy.",
author = "Lee, {Yun Jin} and hoonchul kang and Seo, {Joo Hee} and Lee, {Joon Soo} and HeungDong Kim",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.braindev.2009.02.003",
language = "English",
volume = "32",
pages = "208--212",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "3",

}

Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. / Lee, Yun Jin; kang, hoonchul; Seo, Joo Hee; Lee, Joon Soo; Kim, HeungDong.

In: Brain and Development, Vol. 32, No. 3, 01.03.2010, p. 208-212.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy

AU - Lee, Yun Jin

AU - kang, hoonchul

AU - Seo, Joo Hee

AU - Lee, Joon Soo

AU - Kim, HeungDong

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Purpose: This study investigated the efficacy and safety of zonisamide (ZNS) adjunctive therapy in children with intractable epilepsy to existing antiepileptic drugs (AEDs). Methods: A clinical retrospective study was performed from 2003 to 2005 at two tertiary epilepsy centers. We reviewed the data from 163 children (107 boys and 56 girls) who experienced more than four seizures per month, whose seizures were intractable to an initial 2 or more AEDs, and could be followed up for at least 6. months after ZNS adjunctive therapy initiation. Efficacy was estimated by seizure reduction rate according to seizure types including infantile spasms, and adverse events were also measured. Results: Seventy-nine patients (48.5%) out of 163 patients experienced a reduction in seizure frequency of more than 50%, and 25 patients (15.3%) became seizure-free. The rate of seizure reduction greater than 50% in children with partial seizures was 40.5% (17/42) and in children with generalized seizures was 51.2% (62/121). Of 36 patients who manifested mainly myoclonic seizures, 20 patients (55.6%) showed a seizure reduction of more than 50% and 9 patients (25.0%) were seizure-free. Mean maintenance dosage of drug was 8.2. mg/kg/day (range 5.0-16.0. mg/kg/day). Adverse events were documented in 15 children (9.2%), including somnolence (8 patients), fatigue, and anorexia, but all were transient and successfully managed. One patient discontinued ZNS therapy due to acute pancreatitis. Conclusion: ZNS adjunctive therapy is an effective and safe treatment in various childhood intractable epilepsy.

AB - Purpose: This study investigated the efficacy and safety of zonisamide (ZNS) adjunctive therapy in children with intractable epilepsy to existing antiepileptic drugs (AEDs). Methods: A clinical retrospective study was performed from 2003 to 2005 at two tertiary epilepsy centers. We reviewed the data from 163 children (107 boys and 56 girls) who experienced more than four seizures per month, whose seizures were intractable to an initial 2 or more AEDs, and could be followed up for at least 6. months after ZNS adjunctive therapy initiation. Efficacy was estimated by seizure reduction rate according to seizure types including infantile spasms, and adverse events were also measured. Results: Seventy-nine patients (48.5%) out of 163 patients experienced a reduction in seizure frequency of more than 50%, and 25 patients (15.3%) became seizure-free. The rate of seizure reduction greater than 50% in children with partial seizures was 40.5% (17/42) and in children with generalized seizures was 51.2% (62/121). Of 36 patients who manifested mainly myoclonic seizures, 20 patients (55.6%) showed a seizure reduction of more than 50% and 9 patients (25.0%) were seizure-free. Mean maintenance dosage of drug was 8.2. mg/kg/day (range 5.0-16.0. mg/kg/day). Adverse events were documented in 15 children (9.2%), including somnolence (8 patients), fatigue, and anorexia, but all were transient and successfully managed. One patient discontinued ZNS therapy due to acute pancreatitis. Conclusion: ZNS adjunctive therapy is an effective and safe treatment in various childhood intractable epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=77649183421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649183421&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2009.02.003

DO - 10.1016/j.braindev.2009.02.003

M3 - Article

C2 - 19304420

AN - SCOPUS:77649183421

VL - 32

SP - 208

EP - 212

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 3

ER -